2 studies prove Revlimid's efficacy as maintenance therapy

05/20/2010 | Reuters

The risk of multiple myeloma progression was reduced by more than 50% in stem cell transplant patients who received Celgene's Revlimid as maintenance therapy, two studies showed. One of the clinical trials also noted an 88% survival rate for Revlimid patients after three years, compared with 80% in the group that took a placebo.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Customer Service Director
UCare
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
UCare
Minneapolis, MN
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID